Augmentin

ApprovedSmall molecule

Augmentin is one of 87 small molecule programs targeting Chronic Rhinosinusitis Without Nasal Polyps. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Chronic Rhinosinusitis Without Nasal PolypsActive, not recruiting

Drug-Induced Liver InjuryActive, not recruiting

PneumoniaActive, not recruiting

Otitis MediaActive, not recruiting

Chronic RhinosinusitisActive, not recruiting

Chronic Rhinosinusitis Without Nasal PolypsPreclinical

Active, not recruiting

Drug-Induced Liver InjuryPhase 1

Active, not recruiting

PneumoniaPhase 2

Active, not recruiting

Otitis MediaPreclinical

Active, not recruiting

Chronic RhinosinusitisApproved

Active, not recruiting

Competition

Competitive Landscape

547 competitors in Pneumonia

#DrugCompanyPhaseTrials

Augmentin

Teva

Approved

1 2

Primaxin

Pfizer

Preclinical

2 3

Jakafi

Incyte

Preclinical

1 4

Neutrexin

WWest Japan Thoracic Oncology Group

Preclinical

12 5

Virazole

CConrado Roberto Hoffmann Filho

Preclinical

2 6

Retrovir

BBp Consulting, Inc

Preclinical

2 7

Primsol

CConrado Roberto Hoffmann Filho

Preclinical

2 8

Aciphex

Akero Therapeutics

Preclinical

1 9

Protonix

WWyeth-Lederle Vaccines

Preclinical

1 10

Alka-Seltzer

AAbbott

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2028

Phase 1Active, not recruiting

Labor

NCT05100654

Clinical

Trials by Indication[1]

Fasting Conditions4 trials

Amoxicillin-Clavulanic Acid 400 Mg-57 mg Chewable Tablets Under Non-Fasting Conditions

Completed· Teva logo

Teva·Phase 1·NCT00836901·52 enrolled

Bioequivalence Study of Clavamox, Film-coated Tablets, 875 mg + 125 mg Pharmtechnology LLC, Belarus), and Augmentin®, Film-coated Tablets, 875 mg + 125 mg (GlaxoSmithKline Trading CJSC, Russia), in Healthy Volunteers Under Fasting Conditions

Completed·PPharmtechnology LLC·Phase 1·NCT03702894·56 enrolled

Bioequivalence Study of Clavamox, Powder for Oral Suspension, 400 mg + 57 mg / 5 ml (Pharmtechnology LLC, Belarus), and Augmentin®, Powder for Oral Suspension, 400 mg + 57 mg / 5 ml (GlaxoSmithKline Trading CJSC, Russia), in Healthy Volunteers Under Fasting Conditions

Completed·PPharmtechnology LLC·Phase 1·NCT03616301·56 enrolled

Show 1 more trial

Amoxicillin-Clavulanic Acid 400 Mg-57 mg Chewable Tablets Under Fasting Conditions

Completed· Teva logo

Teva·Phase 1·NCT00835705·52 enrolled

Cholecystectomy1 trial

Prophylactic Antibiotic in Non-complicated Low Risk Lap Cholecystectomy (LC)

Unknown status·—··NCT06193837·200 enrolled

Antibiotic Prophylaxis1 trial

Effects of Antibiotic Prophylaxis on the Healing Parameters Following Surgical Crown Lengthening

Unknown status·—·Phase 4·NCT05925179·28 enrolled

Pneumonia1 trial

Short Duration Treatment of Non-severe Community Acquired Pneumonia

Unknown status·VVersailles Hospital·Phase 2·NCT01963442·310 enrolled

Chronic Rhinosinusitis Without Nasal Polyps1 trial

Oral Steroids in Chronic Rhinosinusitis Without Nasal Polyps

Completed·LLoma Linda University·N/A·NCT02927834·24 enrolled

6 more indications

Chronic Rhinosinusitis1 trial

Duration of Antibiotic Therapy as Part of Maximal Medical Therapy for Chronic Rhinosinusitis

Completed·UUniversity of North Carolina, Chapel Hill·Phase 4·NCT01825408·40 enrolled

Antibiotics1 trial

The Use of Prophylactic Antibiotics In the Management of Dog Bites

Completed·SStanford University·Phase 2/3·NCT00185939·125 enrolled

Labor1 trial

Collaborative Urological Prosthetics Investigation Directive Research Group

Active, not recruiting·UUniversity of Chicago·Phase 1·NCT05100654·800 enrolled

Helicobacter Pylori Infection1 trial

Quadruple Therapy for Triple Therapy Resistant Helicobacter Pylori Infection

Completed·—·N/A·NCT00520949·176 enrolled

Drug-Induced Liver Injury1 trial

A Clinical Study to Explore Biomarkers for Drug-induced Liver Injury (DILI)

Completed·SSeoul National University Hospital·Phase 1·NCT02143323·32 enrolled

Otitis media1 trial

LiveSpo Navax® Supports the Treatment of Acute Rhinosinusitis and Otitis Media

Completed·AAnabio R&D·N/A·NCT05804123·175 enrolled

Sources

References

[1]
ClinicalTrials.gov — 14 trial records for Augmentin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Augmentin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Augmentin. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Teva company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: Teva

Augmentin

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2028

Trials by Indication[1]

Fasting Conditions4 trials

Cholecystectomy1 trial

Antibiotic Prophylaxis1 trial

Pneumonia1 trial

Chronic Rhinosinusitis Without Nasal Polyps1 trial

Chronic Rhinosinusitis1 trial

Antibiotics1 trial

Labor1 trial

Helicobacter Pylori Infection1 trial

Drug-Induced Liver Injury1 trial

Otitis media1 trial

References

Drug Info

Quick Facts

Related News